A minimally replicative HIV-2 live-virus vaccine protects M. nemestrina from disease after HIV-2287 challenge

Abstract

M. nemestrina immunized with an apathogenic HIV-2 molecular clone (HIV- 2(KR)) were protected from CD4 decline and disease upon challenge with HIV- 2287, after any immunizing virus could be detected. Higher but not lower inocula of HIV-2(KR) were protective against intravenous inoculation of either 105 or 101 TCID50 of HIV-2287. Protected animals displayed substantial reductions in PBMC proviral burden (1-3 logs), viral titers (1-2 logs), and plasma viral RNA (2-4 logs) compared to unprotected or naive animals as early as 1 week postinfection. Plasma viral RNA became undetectable after 24 weeks in protected animals, but remained high in unprotected animals. No viral RNA was present in the Spleen of the protected animal necropsied more than a year after challenge (though viral DNA was still present). No neutralizing responses could be demonstrated, but CTL activity was detected sooner and at higher levels after challenge in protected than in unprotected macaques. In this novel HIV-2 vaccine model, protection was clearly dose-dependent, and clearance of challenge virus RNA from the plasma did not require detectable ongoing replication of the immunizing virus at the time of challenge.